首页 / 院系成果 / 成果详情页

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas 期刊论文

编号：

3aca3d13-ac7d-438b-9231-30444ecf7876
作者：

Zhang, Yiliang(张裔良)#^[1,2]Wang, Rui^[1,2];Li, Yuan(李媛)^[2,3]Pan, Yunjian(潘云建)^[1,2]Hu, Haichuan^[1,2];Zhang, Yang^[1,2];Li, Hang^[1,2];Shen, Lei^[2,3];Yu, Yongfu^[4];Sun, Yihua(孙艺华)^[1,2]Chen, Haiquan(陈海泉)*^[1,2]
语种：

English
期刊：

JOURNAL OF THORACIC ONCOLOGY ISSN：1556-0864 2015 年 10 卷 10 期 (1444 - 1450) ; OCT
收录：
关键词：

Thyroid transcription factor 1 Lung adenocarcinoma Subtype Driver mutation Survival
摘要：

Introduction: Thyroid transcription factor 1 (TTF1) is a master regulator of pulmonary differentiation that is downregulated in a subset of lung adenocarcinoma, of which the clinicopathologic characteristics were not fully clarified. Methods: One thousand forty-two lung adenocarcinoma patients who underwent surgery were investigated for clinic characteristics, histologic subtyping, and spectrum of well-identified driver mutations. TTF1 expression was correlated with these clinicopathologic factors and survival. Results: Compared with TTF1 positive (TTF1+) patients, the 133 negative individuals (12.8%, TTF1-) were more likely to be male (p = 0.006) and heavy smokers (p = 0.002) who had larger tumor size (p < 0.001) and more advanced disease stage (p < 0.001). TTF1- presented more in solid and invasive mucinous-predominant carcinomas (both p < 0.001), whereas TTF1+ was identified in 100% patients with adenocarcinoma in situ, minimally invasive and lepidic-predominant adenocarcinomas. The TTF1- tumors harbored the known driver mutations in significantly low frequency compared with TTF1+ adenocarcinomas (57.8% versus 78.1%, p < 0.001), especially in epidermal growth factor receptor (EGFR) mutations (37.6% versus 60.7%, p < 0.001). There was no significant difference in recurrence-free survival between the TTF1- and TTF1+ patients, either for the whole cohort or stratified by pathologic stage, or among the driver mutation-defined subsets. However, recurrence of multiple metastases was more likely to occur in patients with TTF1- adenocarcinomas (88.1% versus 32.4%, p < 0.001). Multivariate analysis revealed that TTF1- independently predicted both poor postrecurrence survival (hazard ratio = 1.664; 95% confidence interval , 1.097-2.524; p = 0.017) and unfavorable overall survival (hazard ratio = 1.553; 95% confidence interval , 1.013-2.381; p = 0.043). Conclusions: TTF1- correlated with solid and invasive mucinous subtypes of lung adenocarcinoma and lower frequency of EGFR mutations. It defines a subgroup of lung adenocarcinomas with unfavorable outcomes.
推荐引用方式
GB/T 7714：

Zhang Yiliang,Wang Rui,Li Yuan, et al. Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas [J].JOURNAL OF THORACIC ONCOLOGY,2015,10(10):1444-1450.
APA：

Zhang Yiliang,Wang Rui,Li Yuan,Pan Yunjian,&Chen Haiquan.(2015).Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas .JOURNAL OF THORACIC ONCOLOGY,10(10):1444-1450.
MLA：

Zhang Yiliang, et al. "Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas" .JOURNAL OF THORACIC ONCOLOGY 10,10(2015):1444-1450.

浏览次数：7  下载次数：0

分享到：

浏览次数：7

下载次数：0

打印次数：0